Kang Sung Soo, Chun Yi Kyeong, Hur Min Hee, Lee Hae Kyung, Kim Yee Jeong, Hong Sung Ran, Lee Jee Hyun, Lee Sung Gong, Park Yong Koo
Department of Surgery, Samsung Cheil Hospital & Women's Healthcare Center, Sungkyunkwan University School of Medicine, 1-19, Mookjung-Dong, Chung-Ku, Seoul, Korea, 100-380.
Jpn J Cancer Res. 2002 Oct;93(10):1123-8. doi: 10.1111/j.1349-7006.2002.tb01214.x.
Glucose uptake and glycolytic metabolism are enhanced in cancer cells compared to normal cells and tissues. Increased expression of glucose transporter 1 (GLUT1) has been reported in human malignant cells. The aim of this study is to determine the expression of the facilitative glucose transporter protein GLUT1 in human breast carcinomas and a possible correlation between GLUT1 expression and clinical outcome including disease-free or overall survival. One hundred consecutive formalin-fixed, paraffin-embedded sections of invasive breast carcinomas were evaluated by means of immunohistochemical staining of GLUT1. Forty-seven (47%) of 100 breast carcinomas showed positive staining for GLUT1. Expression of GLUT1 correlated significantly with nuclear grade (P < 0.001), estrogen receptor status (P = 0.002), and progesterone receptor status (P = 0.001). The mean disease-free survival periods of GLUT1-positive and -negative patients were 47 +/- 2.4 months and 54.3 +/- 1.3 months, respectively (P = 0.017). The mean overall survival periods of GLUT1-positive and -negative patients were 48.7 +/- 2.2 and 56.1+/- 1.3 months, respectively (P = 0.043). In the multivariate analysis, disease-free survival correlated significantly with GLUT1, tumor size, and lymph node involvement (P = 0.043, P = 0.014, and P = 0.045, respectively). In analysis of overall survival, however, lymph node involvement, tumor size, and nuclear grade were statistically significant (P = 0.024, P = 0.023, and P = 0.003, respectively). Our data suggest that absence of GLUT1 expression significantly increases disease-free survival. These findings demonstrate that GLUT1 expression in breast carcinoma can be a marker of aggressive biological behavior and identifies a worse prognosis in breast carcinoma patients.
与正常细胞和组织相比，癌细胞中的葡萄糖摄取和糖酵解代谢增强。据报道，人类恶性细胞中葡萄糖转运蛋白1（GLUT1）的表达增加。本研究的目的是确定易化性葡萄糖转运蛋白GLUT1在人类乳腺癌中的表达，以及GLUT1表达与包括无病生存期或总生存期在内的临床结局之间的可能相关性。通过GLUT1的免疫组织化学染色对100例连续的浸润性乳腺癌福尔马林固定、石蜡包埋切片进行评估。100例乳腺癌中有47例（47%）显示GLUT1染色阳性。GLUT1的表达与核分级（P < 0.001）、雌激素受体状态（P = 0.002）和孕激素受体状态（P = 0.001）显著相关。GLUT1阳性和阴性患者的平均无病生存期分别为47±2.4个月和54.3±1.3个月（P = 0.017）。GLUT1阳性和阴性患者的平均总生存期分别为48.7±2.2个月和56.1±1.3个月（P = 0.043）。在多变量分析中，无病生存期与GLUT1、肿瘤大小和淋巴结受累显著相关（分别为P = 0.043、P = 0.014和P = 0.045）。然而，在总生存期分析中，淋巴结受累、肿瘤大小和核分级具有统计学意义（分别为P = 0.024、P = 0.023和P = 0.003）。我们的数据表明，GLUT1表达缺失显著增加无病生存期。这些发现表明，乳腺癌中GLUT1的表达可能是侵袭性生物学行为的标志物，并提示乳腺癌患者预后较差。
